📊 ECOR Key Takeaways
Is ECOR a Good Investment? Thesis Analysis
electroCore is a pre-revenue profitability company with severe financial distress despite strong gross margins. Negative stockholders' equity of -$1.7M, substantial operating losses of -$13.2M, and negative free cash flow of -$8.3M indicate the company is burning cash faster than it can generate it. While 27.2% revenue growth is notable, it is insufficient to offset mounting operational inefficiencies and the company's unsustainable burn rate.
Why Buy ECOR? Key Strengths
- Strong gross margin of 86.8% demonstrates pricing power and product-market acceptance
- Revenue growth of 27.2% YoY indicates market traction in medical device segment
- Adequate short-term liquidity with current ratio of 1.38x and $7.0M cash reserves
ECOR Investment Risks to Consider
- Negative stockholders' equity of -$1.7M signals insolvency risk and threatens equity holders
- Operating cash flow of -$8.2M with free cash flow margin of -25.8% indicates unsustainable business model
- Total liabilities ($20.4M) exceed total assets ($18.7M) by $1.7M, creating structural balance sheet distress
- Operating margin of -41.1% and net margin of -43.6% demonstrate inability to convert revenue to profitability at scale
Key Metrics to Watch
- Quarterly operating cash flow trend - critical for assessing path to sustainability
- Gross margin trajectory - must remain elevated to justify continued operations
- Quarterly revenue growth rate - deceleration would accelerate path to capital requirement
ECOR Financial Metrics
💡 AI Analyst Insight
electroCore, Inc. presents a mixed fundamental picture. Review the detailed metrics above to form your own investment thesis.
ECOR Profitability Ratios
ECOR vs Healthcare Sector
How electroCore, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is ECOR Overvalued or Undervalued?
Based on fundamental analysis, electroCore, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
ECOR Balance Sheet & Liquidity
ECOR 5-Year Financial Trend & Growth Analysis
5-Year Trend Summary: electroCore, Inc.'s revenue has grown significantly by 488% over the 5-year period, indicating strong business expansion. The most recent EPS of $-1.59 indicates the company is currently unprofitable.
ECOR Growth Metrics (YoY)
ECOR Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $6.6M | -$2.5M | $-0.31 |
| Q2 2025 | $6.1M | -$2.7M | $-0.38 |
| Q1 2025 | $5.4M | -$3.5M | $-0.47 |
| Q3 2024 | $4.5M | -$2.5M | $-0.31 |
| Q2 2024 | $3.6M | -$2.7M | $-0.38 |
| Q1 2024 | $2.8M | -$3.5M | $-0.53 |
| Q3 2023 | $2.0M | -$4.0M | $-0.68 |
| Q2 2023 | $2.2M | -$4.9M | $-1.03 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
ECOR Capital Allocation
ECOR SEC 10-K & 10-Q Filing Analysis
Access official SEC EDGAR filings for electroCore, Inc. (CIK: 0001560258)
📋 Recent SEC Filings
❓ Frequently Asked Questions about ECOR
What is the AI rating for ECOR?
electroCore, Inc. (ECOR) has an AI rating of STRONG SELL with 92% confidence, based on fundamental analysis of SEC EDGAR filings.
What are ECOR's key strengths?
Claude: Strong gross margin of 86.8% demonstrates pricing power and product-market acceptance. Revenue growth of 27.2% YoY indicates market traction in medical device segment.
What are the risks of investing in ECOR?
Claude: Negative stockholders' equity of -$1.7M signals insolvency risk and threatens equity holders. Operating cash flow of -$8.2M with free cash flow margin of -25.8% indicates unsustainable business model.
What is ECOR's revenue and growth?
electroCore, Inc. reported revenue of $32.0M.
Does ECOR pay dividends?
electroCore, Inc. does not currently pay dividends.
Where can I find ECOR SEC filings?
Official SEC filings for electroCore, Inc. (CIK: 0001560258) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is ECOR's EPS?
electroCore, Inc. has a diluted EPS of $-1.65.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is ECOR a good stock to buy right now?
Based on our AI fundamental analysis in March 2026, electroCore, Inc. has a STRONG SELL rating with 92% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is ECOR stock overvalued or undervalued?
Valuation metrics for ECOR: ROE of N/A (sector avg: 15%), net margin of -43.6% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy ECOR stock in 2026?
Our dual AI analysis gives electroCore, Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is ECOR's free cash flow?
electroCore, Inc.'s operating cash flow is $-8.2M, with capital expenditures of $66.0K. FCF margin is -25.8%.
How does ECOR compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -43.6% (avg: 12%), ROE N/A (avg: 15%), current ratio 1.38 (avg: 2).